The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
As official healthcare partner, ShardaCare deployed dedicated medical teams, emergency services, and on-site healthcare infrastructure
First installation of AI-powered AMULET SOPHINITY at NM Medical aims to strengthen early breast cancer detection
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
We are building the bridge between complex molecular data and everyday clinical decisions
The program expected to commence in August 2026 will be offered across multiple specialised areas with an intake of 20-30 students per course
Donor families honoured as Apollo highlights over 27,500 transplants performed and calls for greater public participation in organ donation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
